LV11431B - Central cholecystokinin antagonists for treatment of psychiatric disorders - Google Patents
Central cholecystokinin antagonists for treatment of psychiatric disorders Download PDFInfo
- Publication number
- LV11431B LV11431B LVP-96-32A LV960032A LV11431B LV 11431 B LV11431 B LV 11431B LV 960032 A LV960032 A LV 960032A LV 11431 B LV11431 B LV 11431B
- Authority
- LV
- Latvia
- Prior art keywords
- groups
- alkyl
- hydrogen
- phenyl
- independently
- Prior art date
Links
- 101800001982 Cholecystokinin Proteins 0.000 title description 20
- 229940107137 cholecystokinin Drugs 0.000 title description 15
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title description 15
- 102100025841 Cholecystokinin Human genes 0.000 title description 14
- 239000005557 antagonist Substances 0.000 title description 5
- 208000020016 psychiatric disease Diseases 0.000 title description 2
- 230000001684 chronic effect Effects 0.000 claims abstract description 11
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 5
- 229960003920 cocaine Drugs 0.000 claims abstract description 5
- 229960002715 nicotine Drugs 0.000 claims abstract description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- -1 β-naphthyl Chemical group 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000004414 alkyl thio group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- KDFQABSFVYLGPM-QFIPXVFZSA-N L-365260 Chemical compound N([C@@H]1N=C(C2=CC=CC=C2N(C1=O)C)C=1C=CC=CC=1)C(=O)NC1=CC=CC(C)=C1 KDFQABSFVYLGPM-QFIPXVFZSA-N 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- IEKOTSCYBBDIJC-UHFFFAOYSA-N N(2)-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine Chemical compound CCCCCN(CCCCC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 IEKOTSCYBBDIJC-UHFFFAOYSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 2
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 abstract description 7
- 239000003446 ligand Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003529 diazepam Drugs 0.000 abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 2
- 230000000049 anti-anxiety effect Effects 0.000 abstract description 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 102400000921 Gastrin Human genes 0.000 description 4
- 108010052343 Gastrins Proteins 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 230000010249 dopaminergic function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 3
- 102000052874 Gastrin receptors Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 description 2
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 2
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 229950000165 lorglumide Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical compound C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNQZBKQEIFTHFZ-UHFFFAOYSA-N Loxizin Chemical compound CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 QNQZBKQEIFTHFZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000020426 cherry syrup Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950009386 loxiglumide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (6)
- LV 11431 Izgudrojuma formula 1. D.L-glutamīnskābes un D.L-asparagīnskābes farmakoloģiski aktīvo atvasinājumu ar formulu (I), (ΙΑ), (II) vai (III) vai to farmaceitiski pieņemamo sālu pielietojums anksiofītisku medikamentu ražošanai, kur formulās (I) un (IA) COOH CO-R2 CH2)n (I) I ch-nh-co-Ri (CH2)n (IA) CH-NH-CO-Ri COOH CO-R2 n ir 1 vai 2; R1 ir fenilgrupa, kas aizvietota ar: 1, 2 vai 3 lineārām vai sazarotām Ci^alkilgrupām, kas var būt vienādas vai dažādas, halogēna atomiem, ciāngrupu vai trifluormetilgrupu; R2 ir ņemts no rindas: morfolinilgrupa, piperidinilgrupa vai aminogrupa, kas aizvietota ar vienu vai divām lineārām vai sazarotām vai cikliskām Ci-ealkilgrupām, kas var būt vienādas vai dažādas;formulā (II) 1 R1 ir ūdeņraža atoms, lineāra vai sazarota Ci^alkilgrupa, Ci-5alkenilgrupa, Ci.5alkinilgrupa, -X12COO R6, -X11-C3.7Cikloalkilgrupa, -X12NR4R5, -X12CONR4R , -X12CN vai -X11C(X10)3; R2 ir ūdeņraža atoms, Ci^alkilgrupa, fenilgrupa, kas neobligāti aizvietota ar 1 - 2 halogēna atomiem, Ci.7alkilgrupām, Ci.7alkoksigrupām, Ci.7alkiltiogrupām, karboksilgrupām, karboksi-Ci-7alkilgrupām, nitro-grupām, trifluormetilgrupām vai hidroksilgrupām, 2-, 3- vai 4-piridil-grupa, -X12SCH3, -X12SOCH3, -X12S02CH3, -X12COORe; grupa -X12X2 R3 ir, -X11CX9X11R7, -X11NR18(CH2)qR7, -X11NR18CHCOOR®, -X11X9CX11R7, -NH(CH2)2.3NHR7, -NH(CH2)2.3NHCOR7, -X11NRieS02(CH2)qR7, -X11R7, OH OH I 0 ļ| -X11CHR7 11 ' 7 -X1 C-R7 I -X11CR7 R7 R7a ļ (CH2)q 0 -X11X9CX11R7, 0 -x11cx9x11r7 , | -x11nr18chcoor® , O O 0 nh2 X11X9CCHCH2R7, -X11X9Jx9aX11R7 -x11x9c-ch2-chr7, NHCOOR14 O X2 -X11X9C(CH2)qX9a— J^ļjj 3 , vai =CH-R7, X kur R4 un R5 neatkarīgi viens no otra ir R6 vai grupā NR4R5 kopā ar N atomu abi kopā veido neaizvietotu, mono- vai divaizvietotu, piesātinātu vai nepiesātinātu, vai arī ar benzola gredzenu kondensētu 4-7 locekļu heterociklu, pie kam minētais heterocikls var papildus saturēt otru heteroatomu no rindas: 0 un NCH3, bet minētie aizvietotāji ir neatkarīgi viens no otra ņemti no Ci^alkilgrupām; R® ir ūdeņraža atoms, Ci-7alkilgrupa, CjTcikloalkilgrupa, fenilgrupa vai fenil-Ci-7-alkilgrupa, kas fenilgrupā neobligāti aizvietota ar 1 - 2 halogēna atomiem, 2 LV 11431 Ci.7alkilgrupām, Ci-7alkoksigrupām, nitrogrupām vai trifiuormetilgrupām; R7 un R7a neatkarīgi viens no otra a- vai β-naftilgrupa; fenilgrupa, kas neobligāti aizvietota ar 1 - 2 halogēna atomiem, nitrogrupām, hidroksilgrupām, -X11NR4R5, Ci.7alkilgrupām, trifiuormetilgrupām, ciāngrupām, trifluormetiltiogrupām, etinilgrupām, acetoksigrupām, grupām CH2SCF3, -OCHF2, SH, -SC6H5, -PO3H, Ci-7alkoksigrupām vai Ci-7alkiltiogrupām;R8N N 09ir ūdeņraža atoms, Ci.7alkilgrupa, C3.7cikloalkilgrupa, -X12CONH2, -X12COOR6, -X12-C3-7Cikloalkilgrupa, -X12NR4R5, grupas -X12# -XUCO (CH2) 4f 3 -COCHNHCOOR11 vai -COCHNH- I 12 » 12 ch2r12 ch2r12 R9 un R10 neatkarīgi viens no otra ir ūdeņraža atoms, hidroksilgrupa vai metilgrupa; R11 un R12 neatkarīgi viens no otra ir Ci.7alkilgrupa vai C3-7Cikloalkilgrupa; R13 ir ūdeņraža atoms, Ci.7alkilgrupa, acilgrupa, O vai C3.7cikloalkilgrupa; R14 ir C1-7 alkilgrupa vai fenil-Ci-7alkilgrupa; R15 ir ūdeņraža atoms, C1.7 alkilgrupa, grupavai aminogrupa; R18 ir ūdeņraža atoms, C1.7 alkilgrupa vai acilgrupa; p ir 0, kad blakusesošā grupa =ISF ir nepiesātināta, un 1, kad blakusesošā grupa =N- ir piesātināta, izņemot tādu gadījumu, kad p = 1, R13 ir O un grupa =N- ir nepiesātināta; q ir 0-4; r ir 1 vai 2; XI ir ūdeņraža atoms, nitrogrupa, trifluormetilgrupa, ciāngrupa, hidroksilgrupa, halogēna atoms, Ci-7alkiltiogrupa, Ci^alkoksigrupa, -X11COOR6 vai -X11NR4R5; X2 un X3 neatkarīgi viens no otra ir ūdeņraža atoms, hidroksilgrupa, nitrogrupa, halogēna atoms, Ci-7alkiltiogrupa, Ci^alkilgrupa vai Ci-7alkoksigrupa: X4 irS, O, CH2, NRi8vaiNR8;. X5 ir ūdeņraža atoms, trifluormetilgrupa, ciāngrupa, -COOR6, nitrogrupa vai halogēna atoms; X6 ir O vai HH; X7 ir 0, S, HH vai NR15; X8 ir ūdeņraža atoms vai Ci.7alkilgrupa; X9 un X9a neatkarīgi viens no otra ir NR18vai O; X10 ir F, Cl vai Br; XII nav vispār, vai arī tas ir lineāra vai sazarota Ci^alkilēngrupa; X12 ir lineāra vai sazarota Ci.*alkilēngrupa; = ir piesātināta vai nepiesātināta saite; formulā (III)4 LV 11431 kur R3 R\ R2, R4, R5, R6, R8, R9 R10, R11, R12, R13, R14, R15, p, q, r, X1, X2, X3, X5, X6, X7, X8. X9, X10, X1f un X12 nozīmes ir jau minētās, ir -X11NR1^(CHi)qR16, -NH(CH2)2.3NHR7 -NH(CH2)2.3NHCOR7, -X11NR18CX9aX11R , -X11NR18S02(CH2)qR7, -X11C(=0)R7, grupas 0 0 0 -X11NR18CX11R7 -x11cx9x11r7 , II -x11x9cch-ch2r7 NHCOOR14 onh2 0 „ J I II -X11X9C-CHCH2R7 -X11X9C(CH2)qX9a— -X11C(=0)R R 7 ir a- vai β-naftilgrupa; fenilgrupa, kas neobligāti aizvietota ar 1 - 2 halogēna atomiem, nitrogrupām, hidroksilgrupām, grupām -X11NR4R5, Ci-7alkil-grupām, trifluormetilgrupām, ciāngrupām, trifluormetiltiogrupām, etinilgrupām, acetoksigrupām, grupām CH2SCF3, -OCHF2, SH, SPh, P03H, Ci.7alkoksigrupām, Ci.7alkiltiogrupām vai karboksil-grupām; 0 2-, 3- vai 4-piridilgrupa; ļj OCCS3/ grupa95 R16 ir oc- vai β-naftilgrupa vai 2-indolilgrupa; R18 ir ūdeņraža atoms vai Ci.7alkilgrupa; = ir piesātināta vai nepiesātināta saite.
- 2. Pielietojums pēc 1. punkta, kas atšķiras ar to, ka atvasinājums ir: DL-4-(3,4-dihlorbenzoilamino)-5-(dipentilamino)-5-oksopentānskābe, ^)-4-(3,4-dihlorbenzoilamino)-5-[(3-metoksipropil)pentilamino]-5-oksopentān-skābe, 3(S)-(-)-N-(2,3-dihidro-1 -metil-2-okso-5-fenil-1 H-1,4-benzodiazepin-3-il)-1 H-indol-2-karboksamīds, (R)-N-(2,3-dihidro-1-metil-2-okso-5-fenil-1 H-1,4-benzodiazepin-3-il)-N’-(3-metilfenil)urīnviela vai to farmaceitiski pieņemama sāls.
- 3. Atvasinājuma pēc 1. vai 2. punkta pielietojums tādu medikamentu ražošanai, kas paredzēti zīdītāju abstinences sindroma novēršanai vai ārstēšanai, pārtraucot hronisku ārstēšanu ar dizepāmu.
- 4. Atvasinājuma pēc 1. vai 2. punkta pielietojums tādu medikamentu ražošanai, kas paredzēti zīdītāju abstinences sindroma novēršanai vai ārstēšanai, pārtraucot hronisku kokaīna lietošanu.
- 5. Atvasinājuma pēc 1. vai 2. punkta pielietojums tādu medikamentu ražošanai, kas paredzēti zīdītāju abstinences sindroma novēršanai vai ārstēšanai, pārtraucot hronisku alkohola lietošanu.
- 6. Atvasinājuma pēc 1. vai 2. punkta pielietojums tādu medikamentu ražošanai, kas paredzēti zīdītāju abstinences sindroma novēršanai vai ārstēšanai, pārtraucot hronisku nikotīna lietošanu. 6
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38966589A | 1989-08-04 | 1989-08-04 | |
US42189689A | 1989-10-16 | 1989-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
LV11431A LV11431A (lv) | 1996-08-20 |
LV11431B true LV11431B (en) | 1996-12-20 |
Family
ID=27012795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-96-32A LV11431B (en) | 1989-08-04 | 1996-02-05 | Central cholecystokinin antagonists for treatment of psychiatric disorders |
Country Status (9)
Country | Link |
---|---|
US (1) | US5550126A (lv) |
EP (2) | EP0411668B2 (lv) |
JP (1) | JPH0374328A (lv) |
AT (1) | ATE119040T1 (lv) |
CY (1) | CY1983A (lv) |
DE (1) | DE69017302T3 (lv) |
DK (1) | DK0411668T4 (lv) |
HK (1) | HK8197A (lv) |
LV (1) | LV11431B (lv) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE119040T1 (de) * | 1989-08-04 | 1995-03-15 | Merck Sharp & Dohme | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5399565A (en) * | 1990-07-17 | 1995-03-21 | Eli Lilly And Company | Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof |
US5206238A (en) * | 1990-11-13 | 1993-04-27 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5218115A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5220018A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5218114A (en) * | 1991-04-10 | 1993-06-08 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5220017A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
US5206237A (en) * | 1991-05-14 | 1993-04-27 | Merck & Co., Inc. | Benzodiazepine analogs |
CA2068500A1 (en) * | 1991-05-14 | 1992-11-15 | Roger M. Freidinger | 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings |
US5185331A (en) * | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
US5210082A (en) * | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
WO1992021348A1 (en) * | 1991-06-03 | 1992-12-10 | Merck Sharp & Dohme Limited | Pharmaceutical formulations of a benzodiazepine |
US5177071A (en) * | 1991-06-17 | 1993-01-05 | Merck & Co., Inc. | 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder |
US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
JPH07507993A (ja) * | 1991-12-20 | 1995-09-07 | メルク シヤープ エンド ドーム リミテツド | 医薬活性を有する中枢神経系コレシストキニンアンタゴニスト |
IT1263116B (it) * | 1992-04-09 | 1996-07-30 | Rotta Research Lab | Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico |
WO1993021499A1 (en) * | 1992-04-22 | 1993-10-28 | Copal Company Limited | Absolute encoder |
US5360802A (en) * | 1992-05-11 | 1994-11-01 | Merck Sharpe & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5378838A (en) * | 1993-01-13 | 1995-01-03 | Merck & Co., Inc. | Benzodiazepine cholecystokinin antagonists |
US5852010A (en) * | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5929071A (en) * | 1996-07-02 | 1999-07-27 | Merck & Co., Inc. | Method for the treatment of preterm labor |
AU3591697A (en) * | 1996-07-02 | 1998-01-21 | Merck & Co., Inc. | Method for the treatment of preterm labor |
US6194459B1 (en) | 1997-08-19 | 2001-02-27 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
NZ525513A (en) | 1998-08-07 | 2004-09-24 | Pont Pharmaceuticals Du | Succinoylamino lactams as inhibitors of Abeta protein production |
JP4615727B2 (ja) * | 1998-12-24 | 2011-01-19 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Aβタンパク質生成の阻害剤としてのスクシノイルアミノベンゾジアゼピン |
US7160880B1 (en) | 1999-05-14 | 2007-01-09 | Cenes Limited | Short-acting benzodiazepines |
CA2370141A1 (en) | 1999-05-26 | 2000-12-07 | James D. Rodgers | 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
US6960576B2 (en) * | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
CA2384544A1 (en) | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | Amino lactam sulfonamides as inhibitors of a.beta. protein production |
JP2003523345A (ja) | 2000-02-17 | 2003-08-05 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | Aβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環 |
EP1268433A1 (en) * | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta-protein production |
AU2001253108A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Pharma Company | Cyclic lactams as inhibitors of a-beta protein production |
US20100009966A1 (en) * | 2001-04-11 | 2010-01-14 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of abeta protein production |
WO2001077086A1 (en) * | 2000-04-11 | 2001-10-18 | Dupont Pharmaceuticals Company | SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
AU2001261728A1 (en) * | 2000-05-17 | 2001-11-26 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
AU783857B2 (en) | 2000-06-01 | 2005-12-15 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a beta protein production |
US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
US20030139396A1 (en) * | 2002-01-22 | 2003-07-24 | Karen Gibson | Method of treatment |
US20040167146A1 (en) * | 2002-01-22 | 2004-08-26 | Karen Jackson | Method of treatment |
US6713470B2 (en) * | 2002-01-22 | 2004-03-30 | Ml Laboratories Plc | Method of treatment |
US20040043990A1 (en) * | 2002-04-09 | 2004-03-04 | Karen Jackson | Method of treatment |
KR101155335B1 (ko) * | 2005-01-07 | 2012-06-11 | 엘지전자 주식회사 | 이동통신 단말기의 멀티미디어 메시지 동작방법 |
EP2081921B1 (en) | 2006-07-10 | 2010-09-08 | PAION UK Limited | Short-acting benzodiazepine salts and their polymorphic forms |
NZ580801A (en) * | 2007-05-10 | 2012-09-28 | Bristol Myers Squibb Co | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
CA2929858C (en) | 2013-11-22 | 2022-03-29 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
PT3157928T (pt) | 2014-06-20 | 2019-05-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE57892B1 (en) * | 1984-06-25 | 1993-05-05 | Rotta Research Lab | Glutamic and aspartic acid derivatives |
CA1332410C (en) * | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Benzodiazepine analogs |
US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
IT1215169B (it) * | 1985-12-17 | 1990-01-31 | Rotta Research Lab | Derivati alchil ossigenati degli acidi glutammico ed aspartico ad attivita antagonista su polipeptidi bioattivi e procedimento per la loro preparazione |
IT1217123B (it) * | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
ATE119040T1 (de) * | 1989-08-04 | 1995-03-15 | Merck Sharp & Dohme | Zentrale cholecystokinin-antagonisten zur behandlung von psychiatrischen krankheiten. |
US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
-
1990
- 1990-08-03 AT AT90114993T patent/ATE119040T1/de not_active IP Right Cessation
- 1990-08-03 DE DE69017302T patent/DE69017302T3/de not_active Expired - Fee Related
- 1990-08-03 JP JP2205335A patent/JPH0374328A/ja active Pending
- 1990-08-03 EP EP90114993A patent/EP0411668B2/en not_active Expired - Lifetime
- 1990-08-03 EP EP94106046A patent/EP0727215A3/en not_active Withdrawn
- 1990-08-03 DK DK90114993T patent/DK0411668T4/da active
-
1995
- 1995-01-30 US US08/380,467 patent/US5550126A/en not_active Expired - Fee Related
-
1996
- 1996-02-05 LV LVP-96-32A patent/LV11431B/en unknown
-
1997
- 1997-01-16 HK HK8197A patent/HK8197A/xx not_active IP Right Cessation
- 1997-09-05 CY CY198397A patent/CY1983A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ATE119040T1 (de) | 1995-03-15 |
HK8197A (en) | 1997-01-24 |
EP0727215A3 (en) | 1996-11-06 |
US5550126A (en) | 1996-08-27 |
EP0411668A2 (en) | 1991-02-06 |
EP0411668B1 (en) | 1995-03-01 |
DK0411668T4 (da) | 1999-08-09 |
LV11431A (lv) | 1996-08-20 |
DE69017302D1 (de) | 1995-04-06 |
CY1983A (en) | 1997-09-05 |
DK0411668T3 (da) | 1995-03-27 |
DE69017302T2 (de) | 1995-09-28 |
JPH0374328A (ja) | 1991-03-28 |
EP0727215A2 (en) | 1996-08-21 |
EP0411668A3 (en) | 1992-01-29 |
DE69017302T3 (de) | 1999-08-05 |
EP0411668B2 (en) | 1998-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0411668B1 (en) | Central cholecystokinin antagonists for treatment of psychiatric disorders | |
EP1965865B1 (en) | Combination of an iap-inhibitor and a taxane | |
US5153191A (en) | Cholecystokinin antagonists useful for treating depression | |
TWI791507B (zh) | 使用ccr3-抑制劑治療老化相關損傷之方法及組合物 | |
AU2002351381B2 (en) | Method for treating circadian rhythm disruptions | |
EA028452B1 (ru) | Лечение рака молочной железы | |
AU2004296861A1 (en) | Methods and compositions for slowing aging | |
BRPI0717586A2 (pt) | Método para tratar câncer apresentando mutações do egfr | |
AU2006334731B2 (en) | Combination of triazine derivatives and insulin secretion stimulators | |
WO2008109057A1 (en) | Organic compounds and their uses | |
EP0617621A1 (en) | Central cholecystokinin antagonists having pharmaceutical activity | |
ITMI980086A1 (it) | Composti pirimidin 3-ossido per il trattamento delle patologie muscolo-scheletriche in particolare per il trattamento della | |
KR20070085973A (ko) | 수면 장애 예방 또는 치료제 | |
JPWO2007020935A1 (ja) | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 | |
KR20040025900A (ko) | 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 | |
JP2022501417A (ja) | イオンチャネル阻害化合物を使用して過敏性咳またはかゆみを治療する方法 | |
NZ517949A (en) | Synergistic combinations of an NK1 receptor antagonist and a GABA structural analog | |
GB2196251A (en) | Dioxopiperidine derivatives | |
WO2019139399A1 (ko) | Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
EP0729752A2 (en) | Central cholecystokinin antagonists having pharmaceutical activity | |
KR20040007425A (ko) | 불안 및 공황 장애를 치료하기 위한 비펩티드 봄베신수용체 길항물질의 신규 용도 | |
AU2004273605A1 (en) | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin | |
DK2305654T3 (en) | Therapeutic agent for cancer pain | |
EP0518484A2 (en) | 1,4-Benzodiazepines condesed with 5- and 6-membered heterocyclic rings to treat anxiety, pain, pupil constriction, withdrawal-syndrome or oncologic disorders | |
BR112021004938A2 (pt) | métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3 |